These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 24529525)

  • 1. The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease.
    Hölscher C
    Alzheimers Dement; 2014 Feb; 10(1 Suppl):S47-54. PubMed ID: 24529525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The incretin analogue D-Ala2GIP reduces plaque load, astrogliosis and oxidative stress in an APP/PS1 mouse model of Alzheimer's disease.
    Duffy AM; Hölscher C
    Neuroscience; 2013 Jan; 228():294-300. PubMed ID: 23103794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease.
    McClean PL; Hölscher C
    Neuropharmacology; 2014 Jan; 76 Pt A():57-67. PubMed ID: 23973293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease.
    McClean PL; Hölscher C
    Neuropharmacology; 2014 Nov; 86():241-58. PubMed ID: 25107586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease.
    McClean PL; Parthsarathy V; Faivre E; Hölscher C
    J Neurosci; 2011 Apr; 31(17):6587-94. PubMed ID: 21525299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease.
    Tai J; Liu W; Li Y; Li L; Hölscher C
    Brain Res; 2018 Jan; 1678():64-74. PubMed ID: 29050859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's Disease.
    Hansen HH; Fabricius K; Barkholt P; Kongsbak-Wismann P; Schlumberger C; Jelsing J; Terwel D; Termont A; Pyke C; Knudsen LB; Vrang N
    PLoS One; 2016; 11(7):e0158205. PubMed ID: 27421117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. D-Ala2GIP facilitated synaptic plasticity and reduces plaque load in aged wild type mice and in an Alzheimer's disease mouse model.
    Faivre E; Hölscher C
    J Alzheimers Dis; 2013; 35(2):267-83. PubMed ID: 23568101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease.
    Holscher C
    Recent Pat CNS Drug Discov; 2010 Jun; 5(2):109-17. PubMed ID: 20337586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease.
    Hölscher C
    Biochem Soc Trans; 2011 Aug; 39(4):891-7. PubMed ID: 21787319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer's disease.
    Ji C; Xue GF; Li G; Li D; Hölscher C
    Rev Neurosci; 2016 Jan; 27(1):61-70. PubMed ID: 26351802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotective and restorative properties of the GLP-1/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer's disease.
    Salles GN; Calió ML; Hölscher C; Pacheco-Soares C; Porcionatto M; Lobo AO
    Neuropharmacology; 2020 Jan; 162():107813. PubMed ID: 31628935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Novel DA-CH3 Dual Incretin Restores Endoplasmic Reticulum Stress and Autophagy Impairments to Attenuate Alzheimer-Like Pathology and Cognitive Decrements in the APPSWE/PS1ΔE9 Mouse Model.
    Panagaki T; Gengler S; Hölscher C
    J Alzheimers Dis; 2018; 66(1):195-218. PubMed ID: 30282365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of ageing on neurogenesis and oxidative stress in the APP(swe)/PS1(deltaE9) mouse model of Alzheimer's disease.
    Hamilton A; Holscher C
    Brain Res; 2012 Apr; 1449():83-93. PubMed ID: 22418058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice.
    McClean PL; Jalewa J; Hölscher C
    Behav Brain Res; 2015 Oct; 293():96-106. PubMed ID: 26205827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GIP has neuroprotective effects in Alzheimer and Parkinson's disease models.
    Zhang ZQ; Hölscher C
    Peptides; 2020 Mar; 125():170184. PubMed ID: 31705913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lixisenatide reduces amyloid plaques, neurofibrillary tangles and neuroinflammation in an APP/PS1/tau mouse model of Alzheimer's disease.
    Cai HY; Yang JT; Wang ZJ; Zhang J; Yang W; Wu MN; Qi JS
    Biochem Biophys Res Commun; 2018 Jan; 495(1):1034-1040. PubMed ID: 29175324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noggin and BMP4 co-modulate adult hippocampal neurogenesis in the APP(swe)/PS1(DeltaE9) transgenic mouse model of Alzheimer's disease.
    Tang J; Song M; Wang Y; Fan X; Xu H; Bai Y
    Biochem Biophys Res Commun; 2009 Jul; 385(3):341-5. PubMed ID: 19463786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DA5-CH, a novel GLP-1/GIP dual agonist, effectively ameliorates the cognitive impairments and pathology in the APP/PS1 mouse model of Alzheimer's disease.
    Cao Y; Hölscher C; Hu MM; Wang T; Zhao F; Bai Y; Zhang J; Wu MN; Qi JS
    Eur J Pharmacol; 2018 May; 827():215-226. PubMed ID: 29551659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice.
    Gengler S; McClean PL; McCurtin R; Gault VA; Hölscher C
    Neurobiol Aging; 2012 Feb; 33(2):265-76. PubMed ID: 20359773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.